Flubendazole exhibits anti-glioblastoma effect by inhibiting STAT3 and promoting cell cycle arrest

Area of Science:

• Neuro-oncology
• Cell Biology
• Pharmacology

Background:

• Glioblastoma multiforme (GBM) is an aggressive primary brain tumor with poor patient prognosis.
• Current treatment options for GBM are limited, necessitating novel therapeutic strategies.
• Targeting the cytoskeleton presents a potential avenue for GBM treatment.

Purpose of the Study:

• To investigate the efficacy of the repurposed drug flubendazole (FLU) against GBM cells.
• To elucidate the molecular mechanisms underlying FLU's anti-cancer effects in GBM.
• To evaluate FLU's potential as a therapeutic agent for glioblastoma treatment.

Main Methods:

• In vitro studies using GBM cell lines.
• Assessment of cell proliferation, survival, and cell cycle.
• Analysis of microtubule structure and tubulin expression.
• Investigation of STAT3 and p53 signaling pathways.
• Caspase activity assays.

Main Results:

• Flubendazole (FLU) significantly inhibited GBM cell proliferation and survival.
• FLU affected microtubule structure and influenced tubulin expression.
• FLU decreased STAT3 activation and expression, leading to p53 pathway upregulation.
• FLU induced cell cycle arrest at G2/M phase and caspase-dependent apoptosis in GBM cells.

Conclusions:

• Flubendazole (FLU) demonstrates significant anti-cancer activity against glioblastoma multiforme (GBM) cells.
• The mechanism involves disruption of microtubule dynamics and modulation of key signaling pathways (STAT3, p53).
• FLU shows promise as a potential therapeutic agent for GBM, warranting further clinical investigation.